{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:35:02Z","timestamp":1794440102446,"version":"4.9.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejca.2025.115292","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:08:57Z","timestamp":1738897737000},"page":"115292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy"],"prefix":"10.1016","volume":"218","author":[{"given":"Nicolas","family":"Cabrit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Cheugoua-Zanetsie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nankivell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Wijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.Mark","family":"Smithers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Piessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjen","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent de","family":"Vathaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Urba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Valmasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00e8le","family":"Williaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna van","family":"Sandick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2968","authenticated-orcid":false,"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2025.115292_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"28","key":"10.1016\/j.ejca.2025.115292_bib2","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1200\/JCO.22.02279","article-title":"Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastroesophageal junction carcinoma","volume":"41","author":"Faron","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115292_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.25581","article-title":"Preoperative chemoradiotherapy vs chemotherapy for adenocarcinoma of the esophagogastric junction: a network meta-analysis","volume":"7","author":"Ronellenfitsch","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ejca.2025.115292_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115292_bib5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115292_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.21037\/jtd.2017.01.44","article-title":"A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma","volume":"9","author":"Zheng","year":"2017","journal-title":"J Thorac Dis"},{"issue":"7","key":"10.1016\/j.ejca.2025.115292_bib7","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/jjco\/hyt061","article-title":"Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study)","volume":"43","author":"Nakamura","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115292_bib8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12885-015-1529-x","article-title":"TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG)","volume":"15","author":"Leong","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.115292_bib9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","article-title":"ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)","volume":"16","author":"Hoeppner","year":"2016","journal-title":"BMC Cancer"},{"issue":"17_","key":"10.1016\/j.ejca.2025.115292_bib10","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1","article-title":"Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)","volume":"42","author":"Hoeppner","year":"2024","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.ejca.2025.115292_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40265-017-0728-y","article-title":"Progression-free survival as a surrogate for overall survival in clinical trials of targeted therapy in advanced solid tumors","volume":"77","author":"Michiels","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2025.115292_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2022.04.027","article-title":"Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: a correlation meta-analysis","volume":"170","author":"Ajani","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115292_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2017.01.032","article-title":"Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers","volume":"76","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115292_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejca.2019.10.001","article-title":"Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials","volume":"123","author":"Ronellenfitsch","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.115292_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/1467-9876.00244","article-title":"Validation of surrogate end points in multiple randomized clinical trials with failure time end points","volume":"50","author":"Burzykowski","year":"2001","journal-title":"J R Stat Soc Ser C: Appl Stat"},{"key":"10.1016\/j.ejca.2025.115292_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmpb.2017.12.005","article-title":"surrosurv: an R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials","volume":"155","author":"Rotolo","year":"2018","journal-title":"Comput Methods Prog Biomed"},{"issue":"4","key":"10.1016\/j.ejca.2025.115292_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw239","article-title":"Surrogate end points for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis","volume":"109","author":"Rotolo","year":"2017","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2025.115292_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115292_bib19","article-title":"Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration","author":"Manyara","year":"2024","journal-title":"BMJ"},{"issue":"10302","key":"10.1016\/j.ejca.2025.115292_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ejca.2025.115292_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"9742","key":"10.1016\/j.ejca.2025.115292_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ejca.2025.115292_bib23","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115292_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:37:22Z","timestamp":1777351042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"alternative-id":["S0959804925000735"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115292","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115292"}}